There is no cure for metastatic breast cancer, but there are still many treatment options that may prolong life with reasonable to good preservation of quality of life. To identify suitable treatment options, a tissue biopsy of the metastatic lesion is necessary. Such biopsy is however a burden for the patient, depending on the anatomic site, and may not be representative of other metastatic lesions. Alternatively, a \u201cliquid\u201d biopsy, i.e. blood could be used to find viable treatment options based on circulating tumor DNA. This is now technically feasible and associated with minimal discomfort for the patient. Comparative studies between such liquid and solid biopsies are needed to evaluate whether liquid biopsies are in fact a good alternative for tissue biopsies in metastatic breast cancer patients. Using HMF sequencing data from metastatic tissue lesions (\u201csolid\u201d biopsies), combined with our own analyses of paired blood samples obtained through the Center for Personalised Cancer Treatment (\u201cliquid\u201d biopsies), we will assess whether liquid biopsies are a proper alternative for solid biopsies in metastatic breast cancer patients to identify suitable treatment options.<\/p>\n\n\n\n
Cathy Moelans\u00a0, Universtair Medisch Centrum Utrecht (UMCU), the Netherlands<\/p>\n","protected":false},"author":3,"featured_media":0,"template":"","request_years":[99],"class_list":["post-5382","datarequests","type-datarequests","status-publish","hentry","request_years-99"],"acf":[],"yoast_head":"\n